High-dose

3-Iodobenzylguanidine / therapeutic use Child Child, Preschool Female Humans Japan Kaplan-Meier Estimate Male Neuroblastoma / radiotherapy Radiation Dosage Radiotherapy Dosage Retrospective Studies Risk Treatment Outcome
131I-metaiodobenzylguanidine Internal radiation therapy Radionuclide therapy Refractory neuroblastoma Relapsed neuroblastoma

Journal

Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 07 01 2020
accepted: 18 03 2020
pubmed: 29 3 2020
medline: 12 1 2021
entrez: 29 3 2020
Statut: ppublish

Résumé

The aim of the study was to investigate the outcomes and prognostic factors of high-dose We retrospectively analyzed 20 patients with refractory or relapsed high-risk NBL who underwent In 19 patients with complete follow-up data, the median age at first High-dose

Identifiants

DOI: 10.1007/s12149-020-01460-z PMID: 32219730
pubmed: 32219730
doi: 10.1007/s12149-020-01460-z
pii: 10.1007/s12149-020-01460-z
doi:

Substances chimiques

3-Iodobenzylguanidine 35MRW7B4AD

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

397-406

Auteurs

Daiki Kayano (D)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan. kayano@staff.kanazawa-u.ac.jp.

Hiroshi Wakabayashi (H)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Kenichi Nakajima (K)

Department of Functional Imaging and Artificial Intelligence, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Rie Kuroda (R)

Department of Pediatrics, Kanazawa University Hospital and Department of Pediatrics, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Satoru Watanabe (S)

Department of Functional Imaging and Artificial Intelligence, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Anri Inaki (A)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Ayane Toratani (A)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Norihito Akatani (N)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Takafumi Yamase (T)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.
Department of Radiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa, 920-0293, Japan.

Yuji Kunita (Y)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Tomo Hiromasa (T)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Aki Takata (A)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Hiroshi Mori (H)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Shintaro Saito (S)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Raita Araki (R)

Department of Pediatrics, Ishikawa Prefectural Central Hospital, 2-1 Kuratsuki-Higashi, Kanazawa, Ishikawa, 920-8530, Japan.

Junichi Taki (J)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Seigo Kinuya (S)

Department of Nuclear Medicine, Kanazawa University Hospital and Department of Nuclear Medicine, Institute of Medical, Pharmaceutical and Health Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures halogénés › Hydrocarbures iodés › Iodobenzènes › 3-Iodobenzyl-guanidine › High-dose
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › High-dose
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Enfant d'âge préscolaire › High-dose
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High-dose
questionsmedicales.fr › Régions géographiques › Iles › Japon › High-dose
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Estimation de Kaplan-Meier › High-dose
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Tumeurs neuroectodermiques primitives › Tumeurs neuroectodermiques primitives périphériques › Neuroblastome › High-dose
questionsmedicales.fr › Environnement et santé publique › Santé publique › Hygiène radiologique › Dose de rayonnement › High-dose
questionsmedicales.fr › Thérapeutique › Radiothérapie › Dosimétrie en radiothérapie › High-dose
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › High-dose
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › High-dose
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › High-dose